Search results
Results from the WOW.Com Content Network
"Potentiates digitalis activity, increases coronary dilation effects of theophylline, caffeine, papaverine, sodium nitrate, adenosine and epinephrine, increase barbiturate-induced sleeping times" [3] Horse chestnut: conker tree, conker Aesculus hippocastanum: Liver toxicity, allergic reaction, anaphylaxis [3] Kava: awa, kava-kava [4] Piper ...
Actovegin is a highly filtered extract obtained from calf blood which enhances aerobic oxidation in mammals. [1] This improves absorption of glucose and oxygen uptake in tissue, [1] which may enhance physical performance and stamina.
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]
Benfotiamine (rINN, or S-benzoylthiamine O-monophosphate) is a synthetic, fat-soluble, S-acyl derivative of thiamine (vitamin B1) that is approved in some countries as a medication or dietary supplement to treat diabetic sensorimotor polyneuropathy. Benfotiamine was developed in late 1950s in Japan.
Yohimbine should not be confused with yohimbe [4] but often is. [5]Yohimbe is the common English name for the tree species P. johimbe (also called Corynanthe johimbe) and, by extension, the name of a medicinal preparation made from the bark of that tree, sold as an aphrodisiac. [6]
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
Under the Dietary Supplement Health and Education Act (DSHEA), passed in 1994 in the United States, the Food and Drug Administration (FDA) is not responsible for testing the risks and efficacy of dietary supplements. Manufacturers are not required to present data on the effectiveness of multivitamins or disclose known side effects to the FDA.
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...